Abstract
Background
We are reporting a retrospective analysis of data collected between January 2005- June 2019 from a prospective registry. Of the 845 consecutive patients receiving ICD, 694 patients were included for analysis with a median follow-up of 25 months. This represents nearly 1500 median patient-years of prospectively maintained data over a period of 14 years.
Results
Clinical characteristics: 80% males, 33% diabetes mellitus, 51% hypertension, 15% chronic kidney disease, 10% malignancies, 24% out-of-hospital cardiac arrest, primary prevention in 48% and secondary prevention in 52%, mean LVEF at device implant 37±12% and follow-up 39±13%.
Device implant characteristics: Single chamber in 40%, dual chamber in 35%, CRT-d in 22%, Dx-ICD in 3% & subcutaneous ICD 2%, remote monitoring in 33% patients. Catheter ablation for VT was performed in 13%. Pacemaker complications was noted in 7% in form of pocket revision in 2%, lead revision in 4% and generator malfunction in 1%.
Device therapy characteristics: Therapies were delivered in 35% patients in form of shocks in 72% & ATP in 28%. In those receiving shocks, appropriate shocks were noted in 72% and inappropriate shocks in 28%. Minimum cycle length of the 1st VT was 301±60ms & 2nd episode of VT was 311±56 ms. Mean times to the first therapy was 29 months, first appropriate shock 28 months, and first box change was 70 months.
Survival data: Of the 566 patients with survival data, all-cause mortality was 17.8%, cardiovascular deaths in 53.4%, heart failure in 35.6%, and arrhythmia-related in 17.8%. Mean time-to-death was 63±45 months.
We are reporting a retrospective analysis of data collected between January 2005- June 2019 from a prospective registry. Of the 845 consecutive patients receiving ICD, 694 patients were included for analysis with a median follow-up of 25 months. This represents nearly 1500 median patient-years of prospectively maintained data over a period of 14 years.
Results
Clinical characteristics: 80% males, 33% diabetes mellitus, 51% hypertension, 15% chronic kidney disease, 10% malignancies, 24% out-of-hospital cardiac arrest, primary prevention in 48% and secondary prevention in 52%, mean LVEF at device implant 37±12% and follow-up 39±13%.
Device implant characteristics: Single chamber in 40%, dual chamber in 35%, CRT-d in 22%, Dx-ICD in 3% & subcutaneous ICD 2%, remote monitoring in 33% patients. Catheter ablation for VT was performed in 13%. Pacemaker complications was noted in 7% in form of pocket revision in 2%, lead revision in 4% and generator malfunction in 1%.
Device therapy characteristics: Therapies were delivered in 35% patients in form of shocks in 72% & ATP in 28%. In those receiving shocks, appropriate shocks were noted in 72% and inappropriate shocks in 28%. Minimum cycle length of the 1st VT was 301±60ms & 2nd episode of VT was 311±56 ms. Mean times to the first therapy was 29 months, first appropriate shock 28 months, and first box change was 70 months.
Survival data: Of the 566 patients with survival data, all-cause mortality was 17.8%, cardiovascular deaths in 53.4%, heart failure in 35.6%, and arrhythmia-related in 17.8%. Mean time-to-death was 63±45 months.
| Original language | English |
|---|---|
| Pages (from-to) | 1-1 |
| Number of pages | 1 |
| Journal | Heart Lung and Circulation |
| Volume | 30 |
| DOIs | |
| Publication status | Published - Jan 2021 |
| Event | 69th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand: in conjunction with the 46th Annual Scientific Meeting of the International Society for Heart Research - Adelaide Convention Centre, Adelaide, Australia Duration: 11 Aug 2021 → 14 Aug 2021 https://www.csanzasm.com/ |
